Ascites [clinicaltrials_resource:22eeeb0e2b1ce7adb03126c6df84dff2]
clinicaltrials:NCT00005906North American Study for the Treatment of Refractory Ascites (NASTRA) [clinicaltrials:NCT00006166]clinicaltrials:NCT00108355Renal and Cardiovascular Effects of Terlipressin in Patients With Cirrhosis and Ascites [clinicaltrials:NCT00115947]Prevention of Decompensation in Liver Cirrhosis [clinicaltrials:NCT00239096]clinicaltrials:NCT00327444Cirrhotic Ascites Treatment With Satavaptan in Patients With Ascites Due to Cirrhosis of the Liver (CATS) [clinicaltrials:NCT00358878]Satavaptan in the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver [clinicaltrials:NCT00359437]Satavaptan for the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver [clinicaltrials:NCT00366795]Spontaneous Bacterial Peritonitis: Incidence, Risk Factors and Outcome [clinicaltrials:NCT00490217]Satavaptan Dose-Ranging Study in the Prevention of Ascites [clinicaltrials:NCT00501384]Satavaptan Dose-Ranging Study in Normonatraemic Patients With Cirrhotic Ascites [clinicaltrials:NCT00501566]Satavaptan Dose-Ranging Study in Hyponatraemic Patients With Cirrhotic Ascites [clinicaltrials:NCT00501722]Acute Hemodynamics of Albumin Versus Normal Saline in Cirrhosis [clinicaltrials:NCT00511394]Sodium Restriction in the Management of Cirrhotic Ascites [clinicaltrials:NCT00548366]Effect of Pioglitazone on Portal and Systemic Hemodynamics in Patients With Advanced Cirrhosis [clinicaltrials:NCT00570622]Telesonography Adaptation and Use to Improve the Standard of Patient Care Within a Dominican Community [clinicaltrials:NCT00591968]Effect of Large Volume Paracentesis on Fatigue in Cirrhosis [clinicaltrials:NCT00603200]Spironolactone Versus Spironolactone Plus Furosemide (SVSSF) [clinicaltrials:NCT00741663]Lipopolysaccharide Binding Protein and Development of Infectious Events in Cirrhotic Patients [clinicaltrials:NCT00760032]clinicaltrials:NCT00796861Long-term Follow-up of HALT-C Sustained Virological Responders [clinicaltrials:NCT00825877]The Automated Fluid Shunt (AFS)in Chronic Congestive Heart Failure [clinicaltrials:NCT00907673]Clinical Trial on the Effects of Long Term Administration of 20% Albumin in the Cardiovascular and Renal Function, And Hepatic Hemodynamics in Advanced Patients With Cirrhosis and Ascites. [clinicaltrials:NCT00968695]Safety and Performance of the Automated Fluid Shunt in Patients With Ascites and Diuretic Resistance [clinicaltrials:NCT01030185]Study on B-blockers to Prevent Decompensation of Cirrhosis With HTPortal [clinicaltrials:NCT01059396]Portal Venous Hemodynamic Changes After Hepatectomy [clinicaltrials:NCT01073345]The Influence of Paracentesis on Intra-abdominal Pressure and Kidney Function in Critically Ill Patients With Liver Cirrhosis and Ascites: an Observational Study [clinicaltrials:NCT01091233]B-type Natriuretic Peptide in the Diagnosis of Heart Failure Related Ascites [clinicaltrials:NCT01150916]Impact of Palliative Catheter Placement on the Quality of Life of Patients With Refractory Ascites [clinicaltrials:NCT01188746]clinicaltrials:NCT01236339clinicaltrials:NCT01288794clinicaltrials:NCT01292304clinicaltrials:NCT01331785Dose Exploring and Setting Study for Tolvaptan to Treat Hepatic Cirrhosis With Ascites [clinicaltrials:NCT01349335]Phase III Study of Tolvaptan Tablet to Treat Cirrhosis Ascites [clinicaltrials:NCT01349348]Multiple-dose Pharmacokinetics Study of Tolvaptan Tablets in Chinese Patients With Hepatocirrhosis [clinicaltrials:NCT01359462]clinicaltrials:NCT01403987Conservative Treatment Versus Elective Repair of Umbilical Hernia in Patients With Ascites and Liver Cirrhosis [clinicaltrials:NCT01421550]clinicaltrials:NCT01455246
condition [clinicaltrials_vocabulary:condition]
clinicaltrials:NCT00005906North American Study for the Treatment of Refractory Ascites (NASTRA) [clinicaltrials:NCT00006166]clinicaltrials:NCT00108355Renal and Cardiovascular Effects of Terlipressin in Patients With Cirrhosis and Ascites [clinicaltrials:NCT00115947]Prevention of Decompensation in Liver Cirrhosis [clinicaltrials:NCT00239096]The Use of Drugs to Improve Kidney Function in Patients With Liver and Kidney Dysfunction [clinicaltrials:NCT00240045]clinicaltrials:NCT00326885clinicaltrials:NCT00327444Cirrhotic Ascites Treatment With Satavaptan in Patients With Ascites Due to Cirrhosis of the Liver (CATS) [clinicaltrials:NCT00358878]Satavaptan in the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver [clinicaltrials:NCT00359437]Satavaptan for the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver [clinicaltrials:NCT00366795]Albumin 4 gr/L vs 8 gr/L in the Prevention of Post-Paracentesis Circulatory Dysfunction [clinicaltrials:NCT00428506]Satavaptan Dose-Ranging Study in the Prevention of Ascites [clinicaltrials:NCT00501384]Satavaptan Dose-Ranging Study in Normonatraemic Patients With Cirrhotic Ascites [clinicaltrials:NCT00501566]Satavaptan Dose-Ranging Study in Hyponatraemic Patients With Cirrhotic Ascites [clinicaltrials:NCT00501722]Acute Hemodynamics of Albumin Versus Normal Saline in Cirrhosis [clinicaltrials:NCT00511394]Sodium Restriction in the Management of Cirrhotic Ascites [clinicaltrials:NCT00548366]Adrenal Insufficiency in Cirrhotics With Ascites. Effects of Hydrocortisone on Renal and Haemodynamic Function [clinicaltrials:NCT00657306]Spironolactone Versus Spironolactone Plus Furosemide (SVSSF) [clinicaltrials:NCT00741663]Lipopolysaccharide Binding Protein and Development of Infectious Events in Cirrhotic Patients [clinicaltrials:NCT00760032]clinicaltrials:NCT00796861clinicaltrials:NCT00822809Study in EpCAM Positive Patients With Symptomatic Malignant Ascites Using Removab Versus an Untreated Control Group [clinicaltrials:NCT00836654]A Feasibility Study of the Automated Fluid Shunt (AFS) for Automated Ascites Removal [clinicaltrials:NCT00870662]clinicaltrials:NCT00908219Clinical Trial on the Effects of Long Term Administration of 20% Albumin in the Cardiovascular and Renal Function, And Hepatic Hemodynamics in Advanced Patients With Cirrhosis and Ascites. [clinicaltrials:NCT00968695]Safety and Performance of the Automated Fluid Shunt in Patients With Ascites and Diuretic Resistance [clinicaltrials:NCT01030185]clinicaltrials:NCT01065246Portal Venous Hemodynamic Changes After Hepatectomy [clinicaltrials:NCT01073345]clinicaltrials:NCT01077063The Influence of Paracentesis on Intra-abdominal Pressure and Kidney Function in Critically Ill Patients With Liver Cirrhosis and Ascites: an Observational Study [clinicaltrials:NCT01091233]B-type Natriuretic Peptide in the Diagnosis of Heart Failure Related Ascites [clinicaltrials:NCT01150916]Study of Efficacy of a Vasopressin 2 Receptor Antagonist M0002 for Treatment of Ascites in Cirrhotic Subjects With Hypo- or Normonatraemia [clinicaltrials:NCT01179607]Impact of Palliative Catheter Placement on the Quality of Life of Patients With Refractory Ascites [clinicaltrials:NCT01188746]Bevacizumab as a Palliative Treatment for Patients With Symptomatic Malignant Ascites Due to Advanced-stage Gastrointestinal Cancers [clinicaltrials:NCT01200121]clinicaltrials:NCT01236339Cediranib as Palliative Treatment in Patients With Symptomatic Malignant Ascites or Pleural Effusion [clinicaltrials:NCT01262612]clinicaltrials:NCT01288794clinicaltrials:NCT01292304Endostar and/or Cisplatin for Treatment of Malignant Pleural Effusion or Ascites [clinicaltrials:NCT01327235]
condition browse [clinicaltrials_vocabulary:condition-browse]
clinicaltrials:NCT00005906North American Study for the Treatment of Refractory Ascites (NASTRA) [clinicaltrials:NCT00006166]clinicaltrials:NCT00108355Renal and Cardiovascular Effects of Terlipressin in Patients With Cirrhosis and Ascites [clinicaltrials:NCT00115947]Prevention of Decompensation in Liver Cirrhosis [clinicaltrials:NCT00239096]The Use of Drugs to Improve Kidney Function in Patients With Liver and Kidney Dysfunction [clinicaltrials:NCT00240045]clinicaltrials:NCT00326885clinicaltrials:NCT00327444Cirrhotic Ascites Treatment With Satavaptan in Patients With Ascites Due to Cirrhosis of the Liver (CATS) [clinicaltrials:NCT00358878]Satavaptan in the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver [clinicaltrials:NCT00359437]Satavaptan for the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver [clinicaltrials:NCT00366795]Albumin 4 gr/L vs 8 gr/L in the Prevention of Post-Paracentesis Circulatory Dysfunction [clinicaltrials:NCT00428506]Satavaptan Dose-Ranging Study in the Prevention of Ascites [clinicaltrials:NCT00501384]Satavaptan Dose-Ranging Study in Normonatraemic Patients With Cirrhotic Ascites [clinicaltrials:NCT00501566]Satavaptan Dose-Ranging Study in Hyponatraemic Patients With Cirrhotic Ascites [clinicaltrials:NCT00501722]Acute Hemodynamics of Albumin Versus Normal Saline in Cirrhosis [clinicaltrials:NCT00511394]Sodium Restriction in the Management of Cirrhotic Ascites [clinicaltrials:NCT00548366]Adrenal Insufficiency in Cirrhotics With Ascites. Effects of Hydrocortisone on Renal and Haemodynamic Function [clinicaltrials:NCT00657306]Spironolactone Versus Spironolactone Plus Furosemide (SVSSF) [clinicaltrials:NCT00741663]Lipopolysaccharide Binding Protein and Development of Infectious Events in Cirrhotic Patients [clinicaltrials:NCT00760032]clinicaltrials:NCT00796861clinicaltrials:NCT00822809Study in EpCAM Positive Patients With Symptomatic Malignant Ascites Using Removab Versus an Untreated Control Group [clinicaltrials:NCT00836654]A Feasibility Study of the Automated Fluid Shunt (AFS) for Automated Ascites Removal [clinicaltrials:NCT00870662]clinicaltrials:NCT00908219Clinical Trial on the Effects of Long Term Administration of 20% Albumin in the Cardiovascular and Renal Function, And Hepatic Hemodynamics in Advanced Patients With Cirrhosis and Ascites. [clinicaltrials:NCT00968695]Safety and Performance of the Automated Fluid Shunt in Patients With Ascites and Diuretic Resistance [clinicaltrials:NCT01030185]clinicaltrials:NCT01065246Portal Venous Hemodynamic Changes After Hepatectomy [clinicaltrials:NCT01073345]clinicaltrials:NCT01077063The Influence of Paracentesis on Intra-abdominal Pressure and Kidney Function in Critically Ill Patients With Liver Cirrhosis and Ascites: an Observational Study [clinicaltrials:NCT01091233]B-type Natriuretic Peptide in the Diagnosis of Heart Failure Related Ascites [clinicaltrials:NCT01150916]Study of Efficacy of a Vasopressin 2 Receptor Antagonist M0002 for Treatment of Ascites in Cirrhotic Subjects With Hypo- or Normonatraemia [clinicaltrials:NCT01179607]Impact of Palliative Catheter Placement on the Quality of Life of Patients With Refractory Ascites [clinicaltrials:NCT01188746]Bevacizumab as a Palliative Treatment for Patients With Symptomatic Malignant Ascites Due to Advanced-stage Gastrointestinal Cancers [clinicaltrials:NCT01200121]clinicaltrials:NCT01236339Cediranib as Palliative Treatment in Patients With Symptomatic Malignant Ascites or Pleural Effusion [clinicaltrials:NCT01262612]clinicaltrials:NCT01288794clinicaltrials:NCT01292304Endostar and/or Cisplatin for Treatment of Malignant Pleural Effusion or Ascites [clinicaltrials:NCT01327235]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
eligibility for clinicaltrials:NCT01567709 [clinicaltrials_resource:054d8f683631bdb2773b86e38105e223]eligibility for clinicaltrials:NCT00383266 [clinicaltrials_resource:2e3f4f428109a02e454b1705e9136cd0]eligibility for clinicaltrials:NCT00760032 [clinicaltrials_resource:2f2e7acc2b92af909883821c7e7228e9]eligibility for clinicaltrials:NCT01076543 [clinicaltrials_resource:36da24523cf7bf6b8e9017ef5aff7660]eligibility for clinicaltrials:NCT01460940 [clinicaltrials_resource:3ecd8c0f552ef1a01986cf49e7b89d77]eligibility for clinicaltrials:NCT01557959 [clinicaltrials_resource:4aef4e3e49836e22f2f8d364441730ee]eligibility for clinicaltrials:NCT00041106 [clinicaltrials_resource:6b43d67a0ef8ebcbc7d453df7521ea6f]eligibility for clinicaltrials:NCT02476409 [clinicaltrials_resource:6bce7b29bc1f0e911c7050e8eac6447a]eligibility for clinicaltrials:NCT00086827 [clinicaltrials_resource:a6bdc66e74bdec3a7869289b534b9ef0]eligibility for clinicaltrials:NCT01413503 [clinicaltrials_resource:a82010c7cac6d6059b2d71cf4e655f04]eligibility for clinicaltrials:NCT01038752 [clinicaltrials_resource:b8d66792377e9a4bcd3b92761f701989]eligibility for clinicaltrials:NCT00469898 [clinicaltrials_resource:fc8a97b7fc5ca15a9f8cc842df76c80f]
exclusion criteria [clinicaltrials_vocabulary:exclusion-criteria]
eligibility for clinicaltrials:NCT01567709 [clinicaltrials_resource:054d8f683631bdb2773b86e38105e223]eligibility for clinicaltrials:NCT00047346 [clinicaltrials_resource:065530037b57b66071b90fb20c008095]eligibility for clinicaltrials:NCT00079235 [clinicaltrials_resource:0a710f5bc928c297442f6b3d4cf6f771]eligibility for clinicaltrials:NCT00337194 [clinicaltrials_resource:10ea5c228c130e9bc804de6aefe09754]eligibility for clinicaltrials:NCT00040794 [clinicaltrials_resource:13c6f531d9de8a242be6fb95144c97cf]eligibility for clinicaltrials:NCT00118170 [clinicaltrials_resource:157c62a967817fdc3a16d140edf711c1]eligibility for clinicaltrials:NCT00082966 [clinicaltrials_resource:27c8027e97b7b5713ba5c88d33524a72]eligibility for clinicaltrials:NCT00006486 [clinicaltrials_resource:2935f863adcde7a18a5f18d6b43c7a31]eligibility for clinicaltrials:NCT00383266 [clinicaltrials_resource:2e3f4f428109a02e454b1705e9136cd0]eligibility for clinicaltrials:NCT00760032 [clinicaltrials_resource:2f2e7acc2b92af909883821c7e7228e9]eligibility for clinicaltrials:NCT00025207 [clinicaltrials_resource:3422071272c4c7fe221cb0aba54b180a]eligibility for clinicaltrials:NCT00601900 [clinicaltrials_resource:36b461d136e65a338c35282e995f5614]eligibility for clinicaltrials:NCT01076543 [clinicaltrials_resource:36da24523cf7bf6b8e9017ef5aff7660]eligibility for clinicaltrials:NCT01460940 [clinicaltrials_resource:3ecd8c0f552ef1a01986cf49e7b89d77]eligibility for clinicaltrials:NCT01260688 [clinicaltrials_resource:3f0ebaf7f7cef73daa7b70d582ddfa66]eligibility for clinicaltrials:NCT00470054 [clinicaltrials_resource:447d267c541f5bd31f52aaeb0afbaecc]eligibility for clinicaltrials:NCT00072163 [clinicaltrials_resource:486e53e117286eccc01953ef24c6768c]eligibility for clinicaltrials:NCT01557959 [clinicaltrials_resource:4aef4e3e49836e22f2f8d364441730ee]eligibility for clinicaltrials:NCT00453154 [clinicaltrials_resource:4b000501beb7b60237217dfdd9e04f68]eligibility for clinicaltrials:NCT00134043 [clinicaltrials_resource:4ee031495652de142a93b4905748e504]eligibility for clinicaltrials:NCT00042952 [clinicaltrials_resource:51bacd66798dd95e4640ccb3e6b43beb]eligibility for clinicaltrials:NCT00369655 [clinicaltrials_resource:54be6d2c781973881c050c03266e215a]eligibility for clinicaltrials:NCT01829568 [clinicaltrials_resource:5614567e88f183d31f97ea75d20046a2]eligibility for clinicaltrials:NCT00698815 [clinicaltrials_resource:56235a1d38a15d03b2947ac8c60b7497]eligibility for clinicaltrials:NCT00785291 [clinicaltrials_resource:56e8414e7aae4a3cb51827160e7f935f]eligibility for clinicaltrials:NCT00004856 [clinicaltrials_resource:5eee0b578dec07da2d75cb979931f4cf]eligibility for clinicaltrials:NCT00390455 [clinicaltrials_resource:6784055020d150ff3fa09e30c3cc82cd]eligibility for clinicaltrials:NCT00118183 [clinicaltrials_resource:6a87484a3b083521e9173abd7655be54]eligibility for clinicaltrials:NCT00041106 [clinicaltrials_resource:6b43d67a0ef8ebcbc7d453df7521ea6f]eligibility for clinicaltrials:NCT02476409 [clinicaltrials_resource:6bce7b29bc1f0e911c7050e8eac6447a]eligibility for clinicaltrials:NCT01286272 [clinicaltrials_resource:6d6e6eeb58eeaad063f6bc80559d910a]eligibility for clinicaltrials:NCT00060125 [clinicaltrials_resource:85a3d48d49808d081ae0ca30fa007e31]eligibility for clinicaltrials:NCT00006228 [clinicaltrials_resource:8678da2f44a3087113d5d5816d998565]eligibility for clinicaltrials:NCT00004883 [clinicaltrials_resource:8aeb346dcb893f0a555b1b3b7773666a]eligibility for clinicaltrials:NCT00553644 [clinicaltrials_resource:92674c943fb59dead4ce1a19ed9ebfd3]eligibility for clinicaltrials:NCT00095693 [clinicaltrials_resource:9f0b394b4ef021767fbf635343907b47]eligibility for clinicaltrials:NCT01535924 [clinicaltrials_resource:a1803a9380b1710536c1820dd008106a]eligibility for clinicaltrials:NCT00086827 [clinicaltrials_resource:a6bdc66e74bdec3a7869289b534b9ef0]eligibility for clinicaltrials:NCT00005949 [clinicaltrials_resource:a806e3facb9192d215c3bfe819a85eef]eligibility for clinicaltrials:NCT01413503 [clinicaltrials_resource:a82010c7cac6d6059b2d71cf4e655f04]
inclusion criteria [clinicaltrials_vocabulary:inclusion-criteria]
Ascites [clinicaltrials_resource:22eeeb0e2b1ce7adb03126c6df84dff2]
Bio2RDF identifier
22eeeb0e2b1ce7adb03126c6df84dff2
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:22eeeb0e2b1ce7adb03126c6df84dff2
identifier
clinicaltrials_resource:22eeeb0e2b1ce7adb03126c6df84dff2
title
Ascites
@en
type
label
Ascites [clinicaltrials_resource:22eeeb0e2b1ce7adb03126c6df84dff2]
@en